Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

If you're following the GLP-1 (Ozempic and other prescription weight-loss medications) scene, you may have read that the FDA ...

The metabolic effects of weight management medicines extend beyond appetite regulation. Still, with more questions about ...

Ozempic is hailed as a miracle drug by some people using it to lose weight, however, it isn't suitable for everyone and can ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.